Neurimmune's management team has a proven track record in research and development and partnering.
Dr. Michael Salzmann joined Neurimmune as COO in 2008. Prior to his appointment at Neurimmune, Dr. Salzmann held several positions as senior executive in the private and public sector. He has more than 15 years of industry experience in US and Europe, inter alia with Bruker and Roche. Dr. Salzmann graduated in physics and chemistry, and he was awarded a PhD in biophysics from the ETH Zürich, where he studied with Nobel Laureate Kurt Wüthrich at the Laboratory of Molecular Biology and Biophysics.
Jan Grimm is a neuroscientist with 15 years of experience in drug discovery and development in US and European biotech. Dr. Grimm co-founded Neurimmune in 2006 and served as the company's founding CEO. Before joining Neurimmune he led the Alzheimer’s disease research efforts at Rinat Neuroscience Corp. in San Francisco that was acquired by Pfizer in 2006. He received his PhD from Max Delbrück Center for Molecular Medicine and Humboldt University Berlin.
Dirk Schimkat is an economist with more than 16 years of experience in corporate finance in the consumer goods industry, telecommunications and healthcare. Before joining Neurimmune in 2008, he held a senior position at Beiersdorf’s La Prairie Group in Zurich, a global player in the selective beauty industry. Dirk Schimkat obtained his graduate degree in 1998 from the University of Basel, Switzerland.